首页> 外文OA文献 >Anti-malaria drug development targeting the M1 alanyl and M17 leucyl aminopeptidases
【2h】

Anti-malaria drug development targeting the M1 alanyl and M17 leucyl aminopeptidases

机译:针对M1丙氨酰和M17亮氨酰氨肽酶的抗疟药开发

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The M1 alanyl aminopeptidase and M17 leucyl aminopeptidase are critical to the growth and development of malaria parasites inside host erythrocytes. Potent aminopeptidase inhibitors kill malaria parasites in culture and are also active in vivo against murine malaria. Functional recombinant enzyme studies have been used to decipher the three-dimensional structures of both enzymes that together with new and specific inhibitors are facilitating structure-activity-relationship (SAR) and functional studies. Here we review the progress made in our knowledge of these two enzymes which is bringing them closer to being validated anti-malarial drug targets.
机译:M1丙氨酰氨肽酶和M17亮氨酰肽酶对宿主红细胞内疟原虫的生长和发育至关重要。强大的氨肽酶抑制剂可杀死培养物中的疟疾寄生虫,并且在体内还具有针对鼠类疟疾的活性。功能重组酶研究已用于破译这两种酶的三维结构,这些酶与新型和特异性抑制剂一起促进了结构-活性-关系(SAR)和功能研究。在这里,我们回顾了我们对这两种酶的了解所取得的进展,这使它们更接近于经过验证的抗疟疾药物靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号